<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity default-currency="CAD" hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-301-2-108706-001</iati-identifier>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Developing the captured antigen presentation system as a vaccine against bovine tuberculosis</narrative>
   <narrative xml:lang="FR">D&#xE9;velopper le syst&#xE8;me de pr&#xE9;sentation de l&#x2019;antig&#xE8;ne capt&#xE9; comme vaccin contre la tuberculose bovine</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Bovine tuberculosis is a devastating disease of cattle responsible for major economic losses in Africa and Asia. This disease infects more than 50 million cattle every year, costing US$3 billion annually. The bulk of these losses are in low and middle-income countries. The disease leads to poor agricultural productivity, hinders trade in livestock and livestock products, and can also infect humans who come into contact with unpasteurized products from infected animals. As such, development of an effective vaccine would not only answer to the challenges of constrained livestock production, but it would also protect human life among smallholder farmers and their communities.

There are currently no licensed vaccines against bovine tuberculosis. Attempts to develop vaccines have relied either on using the human live attenuated causative bacteria of a strain known as bacille Calmette Gu&#xE9;rin (BCG), which lacks expression of several potential vaccine antigens; or attempts have depended on the discovery of effective mycobacterial antigens for use as subunit vaccines. To date, no tuberculosis vaccines have been reported to possess better protection than that offered by the BCG vaccine for human use.

This project offers an opportunity to develop a new vaccine by using a new vaccination platform developed by the Wyss Institute. It is based on a captured antigen presentation system (CAPS) comprising two technologies: (1) an artificial lymph node containing a self-assembling scaffold matrix of silica with some components that attract and activate host cells to foreign antigens that become trapped in the artificial lymph node matrix; and (2) magnetic opsonin technology, where cell wall components called pathogen associated molecular patterns &#x2014; derived from bacteria or recombinant antigens &#x2014; are captured using specially coated magnetic beads. Wyss has demonstrated the efficacy of both technologies in mice with a range of pathogens. The project is a collaboration between Wyss Institute at Harvard University and AgResearch Limited (New Zealand). 

This project is funded through the Livestock Vaccine Innovation Fund (LVIF), a partnership between the Bill and Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.</narrative>
   <narrative xml:lang="FR">La tuberculose bovine infecte plus de 50 millions de b&#xEA;tes chaque ann&#xE9;e et co&#xFB;te 3 milliards de dollars am&#xE9;ricains par ann&#xE9;e. La majorit&#xE9; de ces pertes se produisent dans les pays &#xE0; faible revenu et &#xE0; revenu interm&#xE9;diaire. La maladie entra&#xEE;ne une faible productivit&#xE9; agricole, entrave le commerce du b&#xE9;tail et des produits de l&#x2019;&#xE9;levage et peut infecter les humains qui entrent en contact avec des produits non pasteuris&#xE9;s provenant d&#x2019;animaux infect&#xE9;s. Par cons&#xE9;quent, l&#x2019;&#xE9;laboration d&#x2019;un vaccin efficace r&#xE9;pondrait non seulement aux d&#xE9;fis de la production animale limit&#xE9;e, mais prot&#xE9;gerait &#xE9;galement la vie humaine chez les petits agriculteurs et dans leurs communaut&#xE9;s.

Il n&#x2019;existe pas de vaccin homologu&#xE9; contre la tuberculose bovine. Les tentatives de mise au point de vaccins reposent soit sur l&#x2019;utilisation de la bact&#xE9;rie causale humaine vivante att&#xE9;nu&#xE9;e d&#x2019;une souche connue sous le nom de bacille de Calmette et Gu&#xE9;rin (BCG), qui ne comporte pas l&#x2019;expression de plusieurs antig&#xE8;nes vaccinants potentiels; ou les tentatives ont &#xE9;t&#xE9; tributaires de la d&#xE9;couverte d&#x2019;antig&#xE8;nes mycobact&#xE9;riens efficaces pour une utilisation en tant que vaccins sous-unitaires. &#xC0; ce jour, aucun vaccin antituberculeux n&#x2019;offre une meilleure protection que le vaccin BCG chez l&#x2019;homme.

Ce projet offre l&#x2019;occasion de concevoir un nouveau vaccin en utilisant une nouvelle plateforme de vaccination d&#xE9;velopp&#xE9;e par l&#x2019;Institut Wyss. Il est bas&#xE9; sur un syst&#xE8;me de pr&#xE9;sentation d&#x2019;antig&#xE8;ne capt&#xE9; comprenant deux technologies : (1) un ganglion lymphatique artificiel contenant une matrice d&#x2019;&#xE9;chafaudage auto-assemblante de silice avec des composants qui attirent et activent les cellules h&#xF4;tes vers les antig&#xE8;nes &#xE9;trangers, qui sont pi&#xE9;g&#xE9;s dans la matrice ganglionnaire; et (2) la technologie de l&#x2019;opsonine magn&#xE9;tique, o&#xF9; des composants de la paroi cellulaire appel&#xE9;s mod&#xE8;les mol&#xE9;culaires associ&#xE9;s aux agents pathog&#xE8;nes &#x2013; d&#xE9;riv&#xE9;s de bact&#xE9;ries ou d&#x2019;antig&#xE8;nes recombinants &#x2013; sont capt&#xE9;s en utilisant des billes magn&#xE9;tiques comportant un rev&#xEA;tement sp&#xE9;cial. L&#x2019;Institut Wyss a d&#xE9;montr&#xE9; l&#x2019;efficacit&#xE9; des deux technologies chez les souris avec divers pathog&#xE8;nes. 

Ce projet est financ&#xE9; par le Fonds d&#x2019;innovation en mati&#xE8;re de vaccins pour le b&#xE9;tail, un partenariat entre la Fondation Bill et Melinda Gates, Affaires mondiales et le CRDI. Cela repr&#xE9;sente un investissement conjoint de 57 millions de dollars canadiens sur cinq ans pour soutenir la conception, la production et la commercialisation de vaccins novateurs contre les maladies prioritaires qui touchent les animaux d&#x2019;&#xE9;levage en Afrique subsaharienne, en Asie du Sud et en Asie du Sud-Est.</narrative>
  </description>
  <participating-org role="1" type="24">
   <narrative xml:lang="EN">Bill &amp; Melinda Gates Foundation</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="FR">Canada. Affaires mondiales Canada</narrative>
   <narrative xml:lang="EN">Canada. Global Affairs Canada</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="FR">Canada. Parlement</narrative>
   <narrative xml:lang="EN">Canada. Parliament</narrative>
  </participating-org>
  <participating-org role="2" type="80">
   <narrative xml:lang="EN">Harvard College</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Harvard College</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2018-06-01" type="2"></activity-date>
  <activity-date iso-date="2020-12-17" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <email>info@idrc.ca</email>
   <website>http://www.idrc.ca</website>
   <mailing-address>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="1"></activity-scope>
  <recipient-region code="998" percentage="100" vocabulary="1"></recipient-region>
  <sector code="2" percentage="100" vocabulary="99">
   <narrative xml:lang="EN">Increasing food security</narrative>
   <narrative xml:lang="FR">S&#xE9;curit&#xE9; alimentaire</narrative>
  </sector>
  <sector code="31182" percentage="100" vocabulary="1"></sector>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-10"></transaction-date>
   <value currency="CAD" value-date="2019-01-10">436448.35</value>
   <provider-org>
    <narrative xml:lang="EN">Bill &amp; Melinda Gates Foundation</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-10"></transaction-date>
   <value currency="CAD" value-date="2019-01-10">226509.36</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Affaires mondiales Canada</narrative>
    <narrative xml:lang="EN">Canada. Global Affairs Canada</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-10"></transaction-date>
   <value currency="CAD" value-date="2019-01-10">162342.29</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-01-11"></transaction-date>
   <value currency="CAD" value-date="2019-01-11">22111</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-01-11"></transaction-date>
   <value currency="CAD" value-date="2019-01-11">30850</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-01-11"></transaction-date>
   <value currency="CAD" value-date="2019-01-11">70833</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-03-18"></transaction-date>
   <value currency="CAD" value-date="2019-03-18">111239</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-03-18"></transaction-date>
   <value currency="CAD" value-date="2019-03-18">155207</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-03-18"></transaction-date>
   <value currency="CAD" value-date="2019-03-18">356358</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">-133350</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">-186057</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">-427192</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">133350</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">186057</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="CAD" value-date="2020-03-31">427192</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Harvard College</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Grant is conditional on completion of specified terms of reference, receipt of specified deliverables</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de respecter le mandat &#xE9;tabli et de livrer les r&#xE9;sultats attendus</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de p&#xE9;riodiquement pr&#xE9;senter une justification d&#xE9;taill&#xE9;e de l&apos;utilisation des fonds vers&#xE9;s par le CRDI ainsi qu&apos;une estimation budg&#xE9;taire de la p&#xE9;riode de rapport suivante</narrative>
   </condition>
  </conditions>
 </iati-activity>
</iati-activities>
